Answers are grounded in this paper and cite their sources.
Pragmatic and lower daily-dose options are predicted for aztreonam and ceftazidime/avibactam when the eGFR is <90 mL/min. These options should be tested prospectively.
No takes yet. Share an insight, caveat, or question.
Falcone et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: